Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENO1 | P06733 | 3/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28636739 | 0.95 | ENO1 (0.39) | ENO1MMEACECYP3A4TSHR | |
| SCHEMBL23863959 | 0.89 | CYP3A4 (0.44) | ENO1MMEACECYP3A4TSHR | |
| SCHEMBL19296832 | 0.80 | PIK3CD (0.37) | MMEACECYP3A4PIK3CDLMNA | |
| SCHEMBL13074065 | 0.79 | ENO1 (0.47) | ENO1ACECYP3A4TSHRTDP1 | |
| SCHEMBL6294033 | 0.74 | ENO1 (0.42) | ENO1ACECYP3A4TSHRTDP1 | |
| SCHEMBL13074068 | 0.73 | ENO1 (0.41) | ENO1CYP3A4TSHRTDP1MAPT | |
| SCHEMBL28354949 | 0.72 | HSD11B1 (0.43) | MMEACECYP3A4MAPTPIK3CD | |
| SCHEMBL27084766 | 0.72 | PIK3CD (0.39) | MMECYP3A4TSHRMAPTPIK3CD | |
| SCHEMBL12125490 | 0.72 | PIK3CD (0.39) | MMECYP3A4TSHRMAPTPIK3CD | |
| SCHEMBL8468401 | 0.71 | ENO1 (0.40) | ENO1ACECYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, KRAS, HRAS | ENO1 2066/4885MME 2911/4885ACE 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.